A star scientist in the world of single-cell genomics and computational biology is leaving academia to become one of the few women leading R&D at a biotech company.
Aviv Regev, a core institute member of the Broad Institute of MIT and Harvard, will become head of Genentech research and early development effective Aug. 1, its parent company, Roche (RHBBY), announced Monday. She will join the Swiss biopharma company’s corporate executive committee and report to Roche CEO Severin Schwan.
About the Author Reprints
